Alto Neuroscience Inc.
ANRO | NYSE
$30.36
-$0.27 (-0.88%)
Sep 22, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | 210K |
Cost of Revenue | 661K | 502K | n/a | 342K | 145K |
Gross Profit | -661K | -502K | n/a | -342K | 65K |
Operating Income | -66.36M | -68.61M | -37.81M | -29.19M | -12.06M |
Interest Income | 6.6M | 8.85M | 2.35M | 114K | 2K |
Pretax Income | -63.24M | -61.43M | -36.31M | -27.71M | -9.19M |
Net Income | -63.24M | -61.43M | -36.31M | -27.71M | -9.19M |
Selling & General & Admin | 20.75M | 21.61M | 7.52M | 5.16M | 3.75M |
Research & Development | 45.62M | 47M | 30.29M | 23.69M | 8.37M |
Other Expenses | -661K | -502K | n/a | n/a | n/a |
Operating Expenses | 65.7M | 68.11M | 37.81M | 28.85M | 12.12M |
Interest Expense | 2.47M | -1.38M | 1.37M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | -342K | -145K |
Cost & Expenses | 66.36M | 68.61M | 37.81M | 29.19M | 12.27M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 28.85M | 24.6M | 26.88M | 25.57M | 25.57M |
Shares Outstanding (Diluted) | 28.85M | 24.6M | 26.88M | 25.57M | 25.57M |
EPS (Basic) | -2.19 | -2.50 | -1.35 | -1.08 | -0.36 |
EPS (Diluted) | -2.19 | -2.50 | -1.35 | -1.08 | -0.36 |
EBITDA | -60.11M | -62.3M | -34.56M | -27.37M | -9.04M |
EBIT | -60.77M | -62.81M | -34.94M | -27.71M | -9.19M |
Depreciation & Amortization | 661K | 502K | 373K | 342K | 145K |
Add to Watchlist
Select watchlists to add or remove ANRO